Interventions for the treatment of borderline ovarian tumours

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Faluyi, Olusola ^a   Mackean, Melanie ^a   Gourley, Charlie ^a   Bryant, Andrew ^b   Dickinson, Heather O ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SEX HORMONE;

ABDOMINAL HYSTERECTOMY; ALOPECIA; ANEMIA; ANOREXIA; BIBLIOGRAPHIC DATABASE; BLADDER INJURY; BLEEDING; BLOOD TOXICITY; BLOOD VESSEL INJURY; BRAIN TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHEST INFECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON INJURY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG HYPERSENSITIVITY; EXPERIMENTAL THERAPY; FEMALE FERTILITY; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMATOMA; HUMAN; INTERVENTION STUDY; INTESTINE INJURY; INTESTINE OBSTRUCTION; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; LYMPHADENECTOMY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PROCTITIS; PROSPECTIVE STUDY; RADIATION INJURY; RADIATION SICKNESS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SENSITIVITY ANALYSIS; SKIN TOXICITY; STOMATITIS; SURGICAL INJURY; SURGICAL MORTALITY; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URETER INJURY; UROGENITAL TRACT DISEASE; VOMITING;

EID: 70349147068     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007696     Document Type: Review

References (19)

1. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. Journal of Clinical Oncology 2007;25(20):2928-2937
2. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer 2003;97 (Supplement 10):2631-2642
3. CTCAE. Common Terminology Criteria for Adverse Events. (http: //ctep.cancer.gov/forms/CTCAEv3.pdf ) 9th August 2006; Vol. v3.0 (CTCAE).
4. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results fromseveral studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group. 2001.
5. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
6. Benedet JL, Pecorelli S, Ngan HYS, Hacker NF (Editors). Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. FIGO website (http://www.figo.org/docs/staging- booklet.pdf ) last accessed 18.08.2008 2006.
7. Hart WR. Borderline epithelial tumors of the ovary. Modern pathology/ Nature publishing group 2005;18(Supplement 2):S33-S50.
8. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
10. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Cancer 2002;95:2380-2389
11. Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertility and Sterility/ American Society for Reproductive Medicine/Published by Elsevier Science Inc. 2001;75(No 1):92-96 (Pubitemid 32041230)
12. Ødegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstetricia et Gynaecologica Scandinavica 2007;86(5):620-626
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-2834 (Pubitemid 28562978)
14. Partridge EE, Phillips JL, Menck HR. The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 1996;78(10):2236-2246
15. Prat J. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Advances in Anatomical Pathology 1999;6(5):247-274
16. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecologic Oncology 2006;101:255-260
17. Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. American Journal of Surgical Pathology 2006;30(11):1367-1371 (Pubitemid 44655469)
18. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. Journal of National Cancer Institute 2008;100(6):399-406.
19. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. International Journal of Gynecologic Cancer 2007;17 (2):342-49. * Indicates the major publication for the study